Drug discovery group E-therapeutics PLC (LON:ETX) appointed Alison Gallafent as its head of intellectual property.
A UK-chartered patent attorney and European patent attorney, she brings 20-years experience to the role having worked at Merck & Co, Glaxo Wellcome, PLIVA and, more recently, in a similar role at Silence Therapeutics.
E-therapeutics’ chief executive, Ali Mortazavi, said: "We are delighted to welcome Alison to e- therapeutics at this point in the company's evolution. The combination of her broad industry and RNAi expertise will be a major addition to the team."
In the same announcement, investors were told options over 500,000 and 1.25mln shares were granted respectively to Alison Gallafent and Karl Keegan, chief financial officer, who joined the company in March.